SCHEMBL6715798

SCHEMBL6715798

COc1ccc(-c2ccc3cc4n(c3c2)CCNCC4)c(C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.58
HTR2C P28335 4/20 0.58
HTR3E A5X5Y0 2/20 0.44
HTR3B O95264 2/20 0.44
HTR3A P46098 2/20 0.44
HTR3D Q70Z44 2/20 0.44
HTR3C Q8WXA8 2/20 0.44
HTR1A P08908 2/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
MCHR1 Q99705 2/20 0.42
ADRB1 P08588 3/20 0.40
SYK P43405 1/20 0.38
AURKB Q96GD4 1/20 0.38
INCENP Q9NQS7 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
HTR7 P34969 1/20 0.37
ACVR1 Q04771 2/20 0.36
TGFBR1 P36897 2/20 0.35
TLR9 Q9NR96 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716207 0.91 HTR2A (0.58) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL6711320 0.89 HTR2A (0.58) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL6715506 0.88 HTR2A (0.45) HTR2AHTR2CHTR1AMCHR1SYK
SCHEMBL6713937 0.88 HTR2A (0.57) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL6711216 0.88 HTR2A (0.57) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL6715426 0.86 HTR2A (0.52) HTR2AHTR2CHTR3AHTR1AHTR1B
SCHEMBL6714279 0.86 HTR2A (0.55) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL6715702 0.86 HTR2A (0.62) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL26675916 0.86 HTR2A (0.77) HTR2AHTR2CHTR3EHTR3BHTR3A
SCHEMBL6713997 0.85 HTR2A (0.54) HTR2AHTR2CHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US claimed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885HTR3E 13/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885HTR3E 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.